| Document |
Document Title |
|
WO/2022/168670A1 |
The purpose of the present invention is to provide a charge transfer complex which enables the achievement of a curable resin composition that has an excellent balance between curability and storage stability if used as an epoxy resin cu...
|
|
WO/2022/155936A1 |
Disclosed in the present invention is a method for synthesizing an aryl benzyl ether compound, i.e., synthesizing a corresponding aryl benzyl ether compound by means of an oxidative coupling reaction of a phenolic compound and a toluene ...
|
|
WO/2022/155932A1 |
Disclosed is an application of an iron (III) complex containing 1,3-di-tert-butyl imidazolium cation in synthesizing arylbenzyl ether compounds. Specifically, di-tert-butyl peroxide is used as an oxidant, and a corresponding arylbenzyl e...
|
|
WO/2022/140654A1 |
The present disclosure relates to compositions and methods related to bicyclo[2.2.1] heptanamine-containing compounds and salts thereof.
|
|
WO/2022/134297A1 |
The present invention relates to a preparation method for a carboxylate ester compound, comprising: under the catalysis of a nitrite ester, reacting carboxylic acid and methanol in air, so as to obtain an ester compound. The preparation ...
|
|
WO/2022/127038A1 |
Disclosed herein is a method for producing dinitronaphthalene, which includes subjecting naphthalene to a nitration reaction with nitric acid in a reactor, so as to obtain a dinitronaphthalene-containing solution. The reactor includes at...
|
|
WO/2022/121317A1 |
Disclosed is a 1,1'-biphenyl-2,6-diphenolic compound and the use thereof. The 1,1'-biphenyl-2,6-diphenolic compound is a new compound, and has good biological activity. By means of in vitro tumor cell activity experiments, it was found t...
|
|
WO/2022/108984A1 |
The invention relates in particular to methods and intermediates for the synthesis of Compound 1 that inhibits MCL1 and is useful in the treatment of cancers.
|
|
WO/2022/100487A1 |
Disclosed is an amino-combretastatin derivative, and in particular a compound represented by general formula (I), a pharmaceutically acceptable salt thereof, a hydrate thereof, or a hydrate of the pharmaceutically acceptable salt thereof...
|
|
WO/2022/098847A1 |
Disclosed herein are compounds related to tolcapone and its metabolite, 3-OMT, along with 3-deoxytolcapone, as well as pharmaceutical compositions comprising the same. Also disclosed are methods of using such compounds and compositions, ...
|
|
WO/2022/083728A1 |
Disclosed are an intermediate of pregabalin and a preparation method therefor. Provided are a compound as represented by formula (I) and a preparation method therefor. The preparation method for the compound as represented by formula (I)...
|
|
WO/2022/082148A1 |
Processes and systems for producing isomeric mixtures of aromatic amine monomers from aromatic feeds. An example process for producing isomeric mixtures of aromatic amine monomers from aromatic feeds may include nitrating at least a port...
|
|
WO/2022/068057A1 |
Provided is a continuous production method for 2,4-dinitrochlorobenzene. In the method, concentrated nitric acid, concentrated sulfuric acid, and chlorobenzene serve as raw materials; after a mixed acid solution is prepared, chlorobenzen...
|
|
WO/2022/061920A1 |
A method for preparing 3',5'-dichloro-2,2,2-trifluoroacetophenone. The method comprises subjecting 3'-chloro-2,2,2-trifluoroacetophenone as a raw material to four steps, i.e. nitrification, reduction, chlorination and deamination, so as ...
|
|
WO/2022/052683A1 |
The present invention provides a method for preparing a water-soluble magnolol derivative and a honokiol derivative, methods for preparing intermediates of a water-soluble magnolol derivative and a honokiol derivative, and a related mono...
|
|
WO/2022/051317A1 |
Provided herein are processes for synthesizing Mcl-1 inhibitors and intermediates such as compound Y that can be used to prepare them where the variable R1 is as defined herein. In particular, provided herein are processes for synthesizi...
|
|
WO/2021/244136A1 |
Provided in the present invention is a refinement method for nitromethane. The refinement method comprises the following steps: (1) rectifying a nitromethane crude product, and collecting a gas phase fraction for condensation, thus produ...
|
|
WO/2021/237371A1 |
The present application describes process for preparing an ortho-allylated hydroxy aryl compounds such as compounds of Formula (I) by reacting an allylic alcohol with a hydroxy aryl compound in the presence of aluminum compound selected ...
|
|
WO/2021/231582A1 |
The invention features the use of nitro-aminoadamantane compounds for the treatment of negative symptoms and cognitive impairment associated with schizophrenia. A method of treating cognitive impairment associated with schizophrenia (CIA...
|
|
WO/2021/225688A1 |
The present application relates to an analytical method that includes providing a sample potentially containing a chiral analyte that can exist in stereoisomeric forms, providing certain probes; and providing an indicator. The sample is ...
|
|
WO/2021/208951A1 |
Disclosed is a β-diketone cerium (IV) compound of formula (I). The compound has a wide absorption band, is suitable for near ultraviolet-visible region curing as a photoinitiator, and has a high sensitiveness, while also having the adva...
|
|
WO/2021/193952A1 |
This compound has a chain structure in which an aromatic ring group, an ether oxygen, a methylene group, an aromatic ring group, a methylene group, an ether oxygen, and an aromatic ring group are bonded in the listed order. To a carbon o...
|
|
WO/2021/179049A1 |
The present invention relates to the treatment of disorders associated with oxidative stress including neuropathic pain and small synthetically derived compounds for treating such disorders.
|
|
WO/2021/178690A1 |
The invention provides a compound of formula (I): or a salt thereof, wherein A, B, R1, R2, R3 and X have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are usef...
|
|
WO/2021/174748A1 |
The present invention relates to a method for preparing a visible light catalyzed dichlorine addition product of an aliphatic olefin, comprising the following steps: using an aliphatic olefin as a substrate, using copper chloride having ...
|
|
WO/2020/161362A9 |
The disclosure provides a process for the preparation of 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof, contemplated to be capable of modulating the activity of receptors, e.g., PPARs receptors.
|
|
WO/2021/160468A1 |
The present invention relates to a process for the preparation of 1-[4-nitro-2-(trifluoromethyl)- phenyl]-alkanones and substituted phenoxyphenyl ketones.
|
|
WO/2021/160139A1 |
A 9,10-dihydrophenanthrene compound and use thereof in the treatment of liver injury. Specifically, a compound of formula (I) or a compound of formula (II) is provided, which exhibits anti-inflammatory and antioxidant activities in liver...
|
|
WO/2021/127743A1 |
The present disclosure relates to substituted hydroxystilbene compounds and derivatives, specifically 2-substituted hydroxystilbene compounds and derivatives, the synthesis of such compounds and their use in therapy.
|
|
WO/2021/108901A1 |
There is provided the use of a nitro-substituted aromatic compound of formula (I), (II), (III), or (IV) and a copolymers comprising repeat units of formula (III) and/or (IV) as an electrode material as well as the use of such compound in...
|
|
WO/2021/102542A1 |
The present invention relates to the use of nitrates of ethers of glycerol and ethanol as cetane improvers in diesel, and a method for producing same, with a view to producing an additive from glycerol obtained from biodiesel production ...
|
|
WO/2021/102567A1 |
The synthesis of a range of pentylbezene- 1,3-diol compounds of formula I is disclosed. These compounds bind to cannabinoid 1 and 2 receptors (CB1 and CB2), and are thus presumed to be useful in modulating the activity of such receptors....
|
|
WO/2021/082752A1 |
The present invention provides a preparation method for 1-nitro-2-ethyl-4-fluorobenzene. The preparation method comprises the following steps: (1) performing a nitration reaction between m-fluoroacetophenone and a nitration reagent to ob...
|
|
WO/2021/079069A1 |
The present invention relates to novel energetic salts of formula C+A-, wherein: C+ is a cation derived from an amino acid; A- is an energetic nitrogen-containing anion chosen among the anions derived from dinitramide, trinitromethane (N...
|
|
WO/2021/077194A1 |
The present invention relates to the production of carbonyl compounds and derivatives, by means of high yield and purity syntheses, providing antitumour active principles with selective antiproliferative properties and antimestastatic ac...
|
|
WO/2021/074392A1 |
The present invention relates to the field of oncology, laboratory tools and methods, and especially anti-tumor DNA crosslinking agents. Most patients with advanced solid tumors develop resistance to chemotherapy due to the ability of ca...
|
|
WO/2021/066639A1 |
The present invention provides a tryptophan derivative used in agrochemistry, which has a preventive and corrective antiviral effect against begomovirus in plants, does not display phytotoxicity in field concentrations and is not toxic t...
|
|
WO/2021/047978A1 |
The present invention relates to a process for the preparation of α-methyl-[4-(nitro)-2- (trifluoromethyl)]-benzyl nitrate and to the α-methyl-[4-(nitro)-2-(trifluoromethyl)]-benzyl nitrate.
|
|
WO/2021/042411A1 |
Disclosed are an AKR1C3 inhibitor or a pharmaceutically acceptable salt of same, a preparation method for same, and uses thereof. A structural optimization is performed with a nonsteroidal anti-inflammatory medicament, flurbiprofen, serv...
|
|
WO/2021/045207A1 |
The present invention relates to a production method for a highly reactive intermediate. The production method includes: preparing an electron-accepting active compound (1); preparing a piezoelectric material (3); and applying mechanical...
|
|
WO/2021/031431A1 |
Disclosure relates to a use of a fluorination gas, wherein the elemental fluorine is present in a high concentration, for example, in a concentration of elemental fluorine, especially of equal to much higher than 15 % or even 20% by volu...
|
|
WO/2021/019998A1 |
Provided is a compound capable of realizing a lubricant having excellent adhesion to a magnetic disc, especially to a protective layer. A perfluoropolyether compound according to an embodiment of the present invention has a structure in ...
|
|
WO/2021/012689A1 |
Disclosed herein are phenylthiophene sulfonamide compounds, pharmaceutical compositions, a preparation method therefor and use thereof. The compounds of the present invention are capable of effectively and selectively inhibiting Bcl-xL, ...
|
|
WO/2021/000862A1 |
The present invention provides an AKR1C3 inhibitor of compounds of the following formulas and pharmaceutically acceptable salts or solvates or isotopically substituted compounds thereof and medical use.
|
|
WO/2021/001044A1 |
Object of the present invention is an improved process for the preparation of key intermediates for the synthesis of Eltrombopag, passing through/using intermediate 5'-Chloro-2'-hydroxy[1,1'-biphenyl]-3-carboxylic acid alkaline metal sal...
|
|
WO/2020/248127A1 |
A borohydride reduction stabilizing system and a method for reducing an ester to an alcohol. The borohydride reduction stabilizing system comprises: a borohydride reducing agent and a stabilizing agent for stabilizing the borohydride red...
|
|
WO/2020/248279A1 |
The present invention provides a continuous synthesis method for a substituted benzoate organic matter. The continuous synthesis method comprises: in the presence of a catalyst and an organic solvent, continuously feeding an organic matt...
|
|
WO/2020/248278A1 |
The present invention provides a method for the continuous synthesis of a substituted benzoic-acid organic substance. The continuous synthesis method comprises: in the presence of catalyst and organic solvent, the organic matter represen...
|
|
WO/2020/247927A1 |
The current inventive technology includes systems, methods, and compositions for directly synthesizing sticky ended DNA fragments for subsequent gene assembly. In a preferred embodiment, the inventive technology includes strategies for t...
|
|
WO/2020/238862A1 |
The present invention provides a fluorene initiator, a photocurable composition comprising same, and an application thereof. The fluorene photoinitiator has a structure represented by formula (I) or formula (II). In the photoinitiator, o...
|
